Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
18973 | 461 | 37.5 | 79% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
283 | 18382 | EXPERIMENTAL HEMATOLOGY//G CSF//PLERIXAFOR |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MURINE PLASMACYTOMA | Author keyword | 4 | 75% | 1% | 3 |
2 | MICROENCAPSULATED CELLS | Author keyword | 2 | 67% | 0% | 2 |
3 | RECOMBINANT INTERLEUKIN 1 ALPHA | Author keyword | 2 | 67% | 0% | 2 |
4 | Y 25510 | Author keyword | 2 | 67% | 0% | 2 |
5 | MYELODEPRESSION | Author keyword | 1 | 50% | 0% | 2 |
6 | SONICATED TUMOR SUPERNATANT | Author keyword | 1 | 100% | 0% | 2 |
7 | ACTIVE SPECIFIC IMMUNIZATION | Author keyword | 1 | 40% | 0% | 2 |
8 | TUMOR HOST INTERACTIONS | Author keyword | 1 | 21% | 1% | 3 |
9 | ACUTE RADIATION REACTION | Author keyword | 1 | 50% | 0% | 1 |
10 | ANTI P19 | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MURINE PLASMACYTOMA | 4 | 75% | 1% | 3 | Search MURINE+PLASMACYTOMA | Search MURINE+PLASMACYTOMA |
2 | MICROENCAPSULATED CELLS | 2 | 67% | 0% | 2 | Search MICROENCAPSULATED+CELLS | Search MICROENCAPSULATED+CELLS |
3 | RECOMBINANT INTERLEUKIN 1 ALPHA | 2 | 67% | 0% | 2 | Search RECOMBINANT+INTERLEUKIN+1+ALPHA | Search RECOMBINANT+INTERLEUKIN+1+ALPHA |
4 | Y 25510 | 2 | 67% | 0% | 2 | Search Y+25510 | Search Y+25510 |
5 | MYELODEPRESSION | 1 | 50% | 0% | 2 | Search MYELODEPRESSION | Search MYELODEPRESSION |
6 | SONICATED TUMOR SUPERNATANT | 1 | 100% | 0% | 2 | Search SONICATED+TUMOR+SUPERNATANT | Search SONICATED+TUMOR+SUPERNATANT |
7 | ACTIVE SPECIFIC IMMUNIZATION | 1 | 40% | 0% | 2 | Search ACTIVE+SPECIFIC+IMMUNIZATION | Search ACTIVE+SPECIFIC+IMMUNIZATION |
8 | TUMOR HOST INTERACTIONS | 1 | 21% | 1% | 3 | Search TUMOR+HOST+INTERACTIONS | Search TUMOR+HOST+INTERACTIONS |
9 | ACUTE RADIATION REACTION | 1 | 50% | 0% | 1 | Search ACUTE+RADIATION+REACTION | Search ACUTE+RADIATION+REACTION |
10 | ANTI P19 | 1 | 50% | 0% | 1 | Search ANTI+P19 | Search ANTI+P19 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RECOMBINANT HUMAN INTERLEUKIN 1 ALPHA | 18 | 46% | 6% | 29 |
2 | SYNGENEIC TUMORS | 11 | 65% | 2% | 11 |
3 | LINE NIH OVCAR 3 | 4 | 67% | 1% | 4 |
4 | RECOMBINANT INTERLEUKIN 1 ALPHA | 3 | 37% | 2% | 7 |
5 | ANTIBACTERIAL RESISTANCE | 3 | 18% | 3% | 13 |
6 | HISTOINCOMPATIBLE BONE MARROW | 2 | 67% | 0% | 2 |
7 | HEMOPOIETIN 1 | 2 | 25% | 1% | 6 |
8 | INTERLEUKIN 1 INDUCED NONSPECIFIC RESISTANCE | 1 | 100% | 0% | 2 |
9 | MELANOMA HEPATIC METASTASIS | 1 | 100% | 0% | 2 |
10 | SYSTEMIC IL 1 | 1 | 100% | 0% | 2 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Why not treat human cancer with interleukin-1 blockade? | 2010 | 76 | 108 | 16% |
Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects | 1996 | 35 | 37 | 43% |
Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? | 2008 | 85 | 115 | 25% |
Unique versus redundant functional of IL-1 alpha and IL-1 beta in the tumor microenvironment | 2013 | 11 | 100 | 24% |
Interleukin-1 - a major pleiotropic cyrtokine in tumor-host interactions | 2002 | 103 | 98 | 29% |
The role IL-1 in tumor-mediated angiogenesis | 2014 | 16 | 151 | 13% |
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions | 2006 | 176 | 151 | 19% |
Radio- and chemoprotection of bone marrow cells by opposite cell cycle-acting cytokines | 1997 | 18 | 50 | 36% |
Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment | 2006 | 107 | 42 | 21% |
INTERLEUKIN-1 IN THE TREATMENT OF CANCER | 1995 | 13 | 35 | 40% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IMMUNE REGULATOSLO UNIV HOSP | 1 | 50% | 0.2% | 1 |
2 | IMMUNOL10666 N TORREY PINES RD | 1 | 50% | 0.2% | 1 |
3 | SUNNYBROOK HLTH SCI DERMATOL | 1 | 50% | 0.2% | 1 |
4 | UNITE 313 | 1 | 50% | 0.2% | 1 |
5 | VF FOCK PHYS | 1 | 50% | 0.2% | 1 |
6 | CEDARS SINAI MED MED HEMATOL ONCOL | 0 | 33% | 0.2% | 1 |
7 | PHARM NAT SYNTHET DRUGS | 0 | 33% | 0.2% | 1 |
8 | PHARM PHYTOCHEM | 0 | 33% | 0.2% | 1 |
9 | RADIOBIOL PATHOL | 0 | 33% | 0.2% | 1 |
10 | IMM18 | 0 | 25% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000268418 | INTERLEUKIN 1 RECEPTOR ANTAGONIST//IL 1 RECEPTOR ANTAGONIST//LYMPHOKINE RESEARCH |
2 | 0.0000160198 | AS101//SAFDIE AIDS IMMUNOL//CAIR |
3 | 0.0000107542 | G CSF//GM CSF//GRANULOCYTE COLONY STIMULATING FACTOR |
4 | 0.0000100447 | FLT1 PEPTIDE//ANTI FLT1 PEPTIDE//RETINYL |
5 | 0.0000080595 | PCR GENE REARRANGEMENT//PH1 POSITIVE ALL//MED CLIN MOLEC BIOL |
6 | 0.0000075083 | JIXUETENG//SPATHOLOBUS SUBERECTUS DUNN//CHRONIC LOW DOSE IRRADIATION |
7 | 0.0000070143 | HIGH DOSE METHYLPREDNISOLONE//GRP MOL ONCOSURG//AMINOSTEROID |
8 | 0.0000066726 | IL 1RN//INTERLEUKIN 1 BETA GENE//INTERLEUKIN 1B |
9 | 0.0000065510 | MORRIS HEPATOMA 5123//TNF RECEPTORS//ENDOGENOUS TNF ALPHA |
10 | 0.0000060150 | RADIAT COUNTERMEASU PROGRAM//ARMED FORCES RADIOBIOL//ACUTE RADIATION SYNDROME |